Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
<Bundle xmlns="http://hl7.org/fhir">
<id value="bundlepackageleaflet-en-fab45178c60aa670cc4368c283b21dec"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"/>
</meta>
<language value="en"/>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="None"/>
</identifier>
<type value="document"/>
<timestamp value="2023-06-27T10:09:22Z"/>
<entry>
<fullUrl
value="Composition/composition-en-fab45178c60aa670cc4368c283b21dec"/>
<resource>
<Composition>
<id value="composition-en-fab45178c60aa670cc4368c283b21dec"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"/>
</meta>
<language value="en"/>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><a name="Composition_composition-en-fab45178c60aa670cc4368c283b21dec"> </a><p class="res-header-id"><b>Generated Narrative: Composition composition-en-fab45178c60aa670cc4368c283b21dec</b></p><a name="composition-en-fab45178c60aa670cc4368c283b21dec"> </a><a name="hccomposition-en-fab45178c60aa670cc4368c283b21dec"> </a><a name="composition-en-fab45178c60aa670cc4368c283b21dec-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">Language: en</p><p style="margin-bottom: 0px">Profile: <a href="https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1638/001</p><p><b>status</b>: Final</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}">Package Leaflet</span></p><p><b>category</b>: <span title="Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href="Organization-mah-ema.html">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - quviviq</p><h3>Attesters</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{http://hl7.org/fhir/composition-attestation-mode official}">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1638/001"/>
</identifier>
<status value="final"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package Leaflet"/>
</type>
<category>
<coding>
<system
value="http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs"/>
<code value="R"/>
<display value="Raw"/>
</coding>
</category>
<subject>
<reference
value="MedicinalProductDefinition/mpfab45178c60aa670cc4368c283b21dec"/>
</subject>
<date value="2022-02-16T13:28:17Z"/>
<author>🔗
<reference value="Organization/mah-ema"/>
</author>
<title value="TEST PURPOSES ONLY - quviviq"/>
<attester>
<mode>
<coding>
<system
value="http://hl7.org/fhir/composition-attestation-mode"/>
<code value="official"/>
</coding>
</mode>
<time value="2022-02-16T13:28:17Z"/>
</attester>
<section>
<title value="B. Package Leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="B. Package Leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml">unavailable</div>
</text>
<emptyReason>
<coding>
<system
value="http://terminology.hl7.org/CodeSystem/list-empty-reason"/>
<code value="unavailable"/>
</coding>
</emptyReason>
<section>
<title value="Package leaflet: Information for the user"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="Package leaflet: Information for the user"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"></div>
</text>
</section>
<section>
<title value="What is in this leaflet"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="What is in this leaflet"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What is in this leaflet</p><ol type="1"><li>What QUVIVIQ is and what it is used for</li><li>What you need to know before you take QUVIVIQ</li><li>How to take QUVIVIQ</li><li>Possible side effects</li><li>How to store QUVIVIQ</li><li>Contents of the pack and other information</li></ol></div>
</text>
</section>
<section>
<title value="1. What quviviq is and what it is used for"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="1. What quviviq is and what it is used for"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>QUVIVIQ contains the active substance daridorexant, which belongs to the class of medicines called orexin receptor antagonists .</p><p>QUVIVIQ is to treat insomnia in adults.</p><p>How QUVIVIQ works Orexin is a substance produced by the brain that helps keep you awake. By blocking the action of orexin, QUVIVIQ enables you to fall asleep faster and stay asleep longer, and improves your ability to function normally during the day.</p></div>
</text>
</section>
<section>
<title value="2. What you need to know before you take quviviq"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="2. What you need to know before you take quviviq"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Do not take QUVIVIQ</p><ul><li><p>if you are allergic to daridorexant or any of the other ingredients of this medicine (listed in section 6).</p></li><li><p>if you have narcolepsy, a condition that causes you to suddenly and unexpectedly fall asleep at any time.</p></li><li><p>if you are taking medicines which may increase the level of QUVIVIQ in your blood such as:</p></li><li><p>oral medicines to treat fungal infections such as ketoconazole, posaconazole, voriconazole, itraconazole.</p></li><li><p>certain medicines to treat bacterial infections such as the antibiotics clarithromycin, josamycin, telithromycin, troleandomycin.</p></li><li><p>certain medicines to treat HIV infection such as ritonavir, elvitegravir, indinavir, saquinavir, telaprevir, danoprevir, lopinavir, nelfinavir, boceprevir.</p></li><li><p>certain medicines to treat cancer such as ceritinib, idelalisib, ribociclib, tucatinib. Ask your doctor if the medicine you are taking prevents you from taking QUVIVIQ.</p></li></ul><p>Warnings and precautions Talk to your doctor or pharmacist before taking QUVIVIQ if you:</p><ul><li>have depression or have or ever had suicidal thoughts</li><li>have a psychiatric disorder</li><li>currently take medicinal products that affect your brain such as treatments for anxiety or depression</li><li>have regularly taken drugs (except as medicines) or been addicted to drugs or alcohol</li><li>have liver problems: depending on their severity, QUVIVIQ may not be recommended, or a lower dose might be required.</li><li>have breathing difficulties (such as severe obstructive sleep apnoea or severe chronic obstructive pulmonary disease)</li><li>have a history of falling and are older than 65 (because there is generally a higher risk of falling in patients > 65). Your doctor may want to monitor how the medicine affects you.</li></ul><p>Tell your doctor if you get any of the following side effects while taking QUVIVIQ:</p><ul><li>sleep paralysis: a temporary inability to move or talk for up to several minutes upon awakening or falling asleep</li><li>hallucinations: seeing or hearing vivid or disturbing things that are not real upon awakening or falling asleep</li></ul><p>If you have depression and you experience a worsening or have thoughts of harming yourself, call your doctor straight away.</p><p>Children and adolescents This medicine is not for children and adolescents under 18 years of age because QUVIVIQ has not been tested in this age group.</p><p>Other medicines and QUVIVIQ Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines because:</p><ul><li>certain antibiotics (erythromycin, ciprofloxacin, clarithromycin, rifampicin), immuno- suppressants (cyclosporine), antifungal agents (itraconazole), cancer treatments (ceritinib), or HIV treatments (ritonavir, efavirenz) can increase or decrease the level of QUVIVIQ in the blood. Some of these medicines may be contra-indicated with QUVIVIQ (see section Do not take QUVIVIQ ). Your doctor will advise you on this.</li><li>certain medicines that work in your brain (e.g., diazepam, alprazolam) could interact with QUVIVIQ. Your doctor will advise you on this.</li><li>certain medicines to treat blood coagulation disorder such as dabigatran could interact with QUVIVIQ, which would require some precaution. Your doctor will advise you on this.</li><li>certain medicines to treat cardiac impairment such as digoxin could interact with QUVIVIQ, which would require some precaution. Your doctor will advise you on this.</li></ul><p>QUVIVIQ with food, drink and alcohol Drinking alcohol with QUVIVIQ can increase the risk of impaired balance and coordination.</p><p>Avoid grapefruit or grapefruit juice in the evening as they may increase the level of QUVIVIQ in the blood.</p><p>Pregnancy, breast-feeding and fertility If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before taking this medicine.</p><p>It is not known if QUVIVIQ can harm your unborn baby.</p><p>It is not known if QUVIVIQ passes into your breast milk. Talk to your doctor about the best way to feed your baby during treatment with QUVIVIQ.</p><p>It is not known if QUVIVIQ affects human fertility.</p><p>Driving and using machines A period of approximately 9 hours is recommended between taking QUVIVIQ and driving or using machines. Be cautious about driving or using machines in the morning after taking QUVIVIQ. Do not engage in potentially hazardous activities if you are not sure you are fully alert, especially in the first few days of treatment.</p><p>QUVIVIQ contains sodium This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially sodium- free .</p></div>
</text>
</section>
<section>
<title value="3. How to take quviviq"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="3. How to take quviviq"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>How much QUVIVIQ to take Your doctor will advise you on the dose of QUVIVIQ to take.</p><p>The recommended dose is one 50-mg tablet of QUVIVIQ per night.</p><p>If you have liver problems or take certain other medicines, your doctor may prescribe you a lower dose of one 25-mg tablet of QUVIVIQ per night.</p><p>The treatment duration should be as short as possible. The appropriateness of continued treatment will be assessed within 3 months by your doctor and periodically thereafter.</p><ul><li>Take QUVIVIQ, one time per night, by mouth, in the half hour before going to bed at night.</li><li>You can take QUVIVIQ with or without food, however it may take longer to work if you take it with or right after a large meal.</li></ul><p>If you take more QUVIVIQ than you should If you take more QUVIVIQ than you should, you may experience excessive sleepiness and muscle weakness. Contact your doctor straight away.</p><p>If you forget to take QUVIVIQ If you forget to take QUVIVIQ at bedtime, then you should not take it later during the night, otherwise you may feel drowsy in the morning. Do not take a double dose to make up for a forgotten tablet.</p><p>If you stop taking QUVIVIQ Treatment with QUVIVIQ can be stopped without a need to gradually reduce the dose, and without harmful effects.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p></div>
</text>
</section>
<section>
<title value="4. Possible side effects"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="4. Possible side effects"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them. The following side effects may happen with this medicine:</p><p>Common (may affect up to 1 in 10 people):</p><ul><li>headache</li><li>excessive sleepiness</li><li>dizziness</li><li>tiredness</li><li>feeling sick (nausea)</li></ul><p>Uncommon (may affect up to 1 in 100 people):</p><ul><li>temporary inability to move or talk (sleep paralysis) for up to several minutes while you are going to sleep or waking up (see section 2).</li><li>seeing or hearing vivid or disturbing things that are not real (hallucinations; see section 2)</li></ul><p>Please talk to your doctor if either of these happen to you.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.</p></div>
</text>
</section>
<section>
<title value="5. How to store quviviq"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="5. How to store quviviq"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and blister after EXP.<br/>The expiry date refers to the last day of that month.</p><p>This medicine does not require any special storage conditions.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer require. These measures will help to protect the environment.</p></div>
</text>
</section>
<section>
<title value="6. Contents of the pack and other information"/>
<code>
<coding>
<system value="https://spor.ema.europa.eu/rmswi/"/>
<code value="100000155538"/>
</coding>
<text value="6. Contents of the pack and other information"/>
</code>
<text>
<status value="additional"/>
<div xmlns="http://www.w3.org/1999/xhtml"><p>What QUVIVIQ contains<br/>The active substance is daridorexant.</p><p>QUVIVIQ 25 mg film-coated tablets<br/>Each tablet contains daridorexant hydrochloride, equivalent to 25 mg of daridorexant.</p><p>QUVIVIQ 50 mg film-coated tablets<br/>Each tablet contains daridorexant hydrochloride, equivalent to 50 mg of daridorexant.</p><p>The other ingredients are:<br/>Tablet cores: Mannitol (E421), microcrystalline cellulose (E460), povidone, croscarmellose sodium (see section 2 QUVIVIQ contains sodium ), silicon dioxide, magnesium stearate.</p><p>Film coating: Hypromellose (E464), microcrystalline cellulose (E460), glycerol, talc (E553), titanium dioxide (E171), iron oxide red (E172), iron oxide black (E172), iron oxide yellow (E172; 50 mg tablets only).</p><p>What QUVIVIQ looks like and contents of the pack Film-coated tablet (tablet)</p><p>QUVIVIQ 25 mg film-coated tablets<br/>Light purple, triangular tablet with 25 on one side, and i (Idorsia logo) on the other side.</p><p>QUVIVIQ 50 mg film-coated tablets<br/>Light orange, triangular tablet with 50 on one side, and i (Idorsia logo) on the other side.</p><p>QUVIVIQ is available in blister packs of 10, 20 or 30 film-coated tablets.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder Idorsia Pharmaceuticals Deutschland GmbH Marie-Curie-Strasse 8 79539 L rrach Germany</p><p>Manufacturer Idorsia Pharmaceuticals Deutschland GmbH Marie-Curie-Strasse 8 79539 L rrach Germany</p><p>PharmaKorell GmbH Georges-Koehler-Str. 2 79539 L rrach Germany</p><p>This leaflet was last revised in</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>
</text>
</section>
</section>
</Composition>
</resource>
</entry>
<entry>
<fullUrl
value="MedicinalProductDefinition/mpfab45178c60aa670cc4368c283b21dec"/>
<resource>
<MedicinalProductDefinition>
<id value="mpfab45178c60aa670cc4368c283b21dec"/>
<meta>
<profile
value="http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"/>
</meta>
<text>
<status value="generated"/>
<div xmlns="http://www.w3.org/1999/xhtml"><a name="MedicinalProductDefinition_mpfab45178c60aa670cc4368c283b21dec"> </a><p class="res-header-id"><b>Generated Narrative: MedicinalProductDefinition mpfab45178c60aa670cc4368c283b21dec</b></p><a name="mpfab45178c60aa670cc4368c283b21dec"> </a><a name="hcmpfab45178c60aa670cc4368c283b21dec"> </a><a name="mpfab45178c60aa670cc4368c283b21dec-en-US"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/22/1638/001</p><p><b>type</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}">Medicinal Product</span></p><p><b>domain</b>: <span title="Codes:{http://hl7.org/fhir/medicinal-product-domain Human}">Human use</span></p><p><b>status</b>: <span title="Codes:{http://hl7.org/fhir/publication-status active}">active</span></p><p><b>legalStatusOfSupply</b>: <span title="Codes:{https://spor.ema.europa.eu/rmswi 100000072084}">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: QUVIVIQ 25 mg film-coated tablets</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title="Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class="grid"><tr><td style="display: none">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style="display: none">*</td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:iso:std:iso:3166 EU}">EU</span></td><td><span title="Codes:{urn:ietf:bcp:47 en}">en</span></td></tr></table></blockquote></div>
</text>
<identifier>
<system value="http://ema.europa.eu/identifier"/>
<value value="EU/1/22/1638/001"/>
</identifier>
<type>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-type"/>
<code value="MedicinalProduct"/>
<display value="Medicinal Product"/>
</coding>
</type>
<domain>
<coding>
<system value="http://hl7.org/fhir/medicinal-product-domain"/>
<code value="Human"/>
<display value="Human use"/>
</coding>
</domain>
<status>
<coding>
<system value="http://hl7.org/fhir/publication-status"/>
<code value="active"/>
<display value="active"/>
</coding>
</status>
<legalStatusOfSupply>
<coding>
<system value="https://spor.ema.europa.eu/rmswi"/>
<code value="100000072084"/>
<display
value="Medicinal product subject to medical prescription"/>
</coding>
</legalStatusOfSupply>
<name>
<productName value="QUVIVIQ 25 mg film-coated tablets"/>
<type>
<coding>
<system value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000001"/>
<display value="Full name"/>
</coding>
</type>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000002"/>
<display value="Invented name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000003"/>
<display value="Scientific name part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000004"/>
<display value="Strength part"/>
</coding>
</type>
</part>
<part>
<part value="nan"/>
<type>
<coding>
<system
value="https://spor.ema.europa.eu/lists/220000000000"/>
<code value="220000000005"/>
<display value="Pharmaceutical dose form part"/>
</coding>
</type>
</part>
<usage>
<country>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</country>
<jurisdiction>
<coding>
<system value="urn:iso:std:iso:3166"/>
<code value="EU"/>
<display value="EU"/>
</coding>
</jurisdiction>
<language>
<coding>
<system value="urn:ietf:bcp:47"/>
<code value="en"/>
<display value="en"/>
</coding>
</language>
</usage>
</name>
</MedicinalProductDefinition>
</resource>
</entry>
</Bundle>
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
